Quantcast

Latest Ristocetin Stories

2010-08-02 08:00:00

HOBOKEN, N.J., Aug. 2 /PRNewswire/ -- Octapharma USA has received confirmation of orphan drug exclusivity from the U.S. Food and Drug Administration (FDA) for wilate® (von Willebrand Factor/Factor VIII Concentrate, Human), the replacement therapy developed specifically for von Willebrand Disease (VWD). The approval comes from the FDA Office of Orphan Products Development, which helps to advance the development of products that demonstrate promise for the treatment of rare...

2010-01-13 10:00:00

LACHEN, Switzerland, Jan. 13 /PRNewswire/ -- Octapharma AG, one of the largest manufacturers of plasma products in the world, today announced that it has received orphan drug exclusivity approval for wilate® from the U.S. Food and Drug Administration (FDA). The approval was granted for the use of wilate® for the treatment of spontaneous or trauma-induced bleeding episodes in patients with severe von Willebrand disease (VWD) as well as in patients with...

2009-12-07 11:00:00

HOBOKEN, N.J., Dec. 7 /PRNewswire/ -- Octapharma USA today announced the U.S. Food and Drug Administration has approved wilate® for the treatment of spontaneous and trauma-induced bleeding episodes in patients with all types of von Willebrand disease (VWD). Wilate® is a newly developed, high-purity, double virus inactivated von Willebrand Factor/Coagulation Factor VIII Concentrate (Human) that demonstrated efficacy for all types of VWD, including...

2009-06-30 08:12:00

vW Select Significantly Reduces Laboratory Variability and Provides Clinicians with More Reliable Test Results HORSHAM, Pa., June 30 /PRNewswire/ -- Today, Bio/Data Corporation announced the launch of vW Select(TM), the world's first all-in-one Ristocetin CoFactor Assay. vW Select is the first and only complete assay that measures the functional activity of the von Willebrand Factor. A deficiency of von Willebrand Factor causes von Willebrand Disease -- the world's most common bleeding...

2008-08-18 09:00:16

KING OF PRUSSIA, Pa., Aug. 18 /PRNewswire/ -- CSL Behring is providing a $1.2 million grant to fund a first-of-its kind, nationwide study that when completed could serve as the basis for determining optimal prophylaxis treatment for postpartum women with von Willebrand disease (VWD). Investigators anticipate that the study results will produce a better understanding of the physiology of VWD in the postpartum period, whether treatment is needed and, if so, for how long. To view the...


Word of the Day
drawcansir
  • A blustering, bullying fellow; a pot-valiant braggart; a bully.
This word is named for Draw-Can-Sir, a character in George Villiers' 17th century play The Rehearsal.
Related